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Primary liver cancer is the sixth most commonly occurring cancer in the world and the third most common 
cause of cancer-related mortality.1 In 2013, 
20.9 million disability life years (DALYs) were 
attributed to liver cancer globally. While 
86% of this burden of disease is experienced 
in developing countries,1 there are clear 
indications that incidence of liver cancer is 
increasing in developed countries. In the 
US, the age-standardised incidence rate 
increased from 4.9 per 100,000 persons in 
1999 to 8.3 per 100,000 in 2015.2 
Similar trends have been observed for 
Australia. A recently published study reported 
age-adjusted incidence of hepatocellular 
carcinoma (HCC) – the most common form 
of primary liver cancer – increased from 
1.38/100,000 persons in 1982 to 4.96/100,000 
in 2014.3 In Victoria, the second most 
populous state in Australia, incidence of HCC 
increased sixfold from 0.9/100,000 persons to 
5.9/100,000 persons between 1982 and 2013.4 
An older study based on data from the New 
South Wales Central Cancer Registry reported 
incidence of HCC among people with chronic 
hepatitis B or C increased from 1.4/100,000 
persons in 1990 to 2.8/100,000 persons in 
2002, with the greatest burden for people 
born in Vietnam.5 Further, age-standardised 
mortality rates have been projected to 
increase for males from 9.0/100,000 persons 
in 2014 to 11.8/100,000 persons in 2025; 
and for females, from 3.8/100,000 persons to 
4.9/100,000 persons.6 
The disease burden associated with HCC 
is highest in areas with endemic hepatitis 
B (HBV) (i.e. HBsAg prevalence > 6%), such 
as in sub-Saharan Africa and Asia, with 
HCC incidence rates of over 20 per 100,000 
individuals.7-9 In regions of high incidence, 
the most common cause is HBV transmitted 
at birth, i.e. vertical transmission. In 
comparison to North American and European 
populations – where the most common 
aetiology is hepatitis C (HCV) acquired later in 
life – diagnosis of HCC occurs approximately 
one decade earlier among populations 
with prevalent vertical transmission.9,10 For 
example, the mean age interval at diagnosis 
of HCC in China is 55 to 59 years; in Europe 
and North America this range is 63 to 65 
years, and among low-risk populations 
75+ years.10 HCC is more common in men 
than women as HBV, HCV, and alcohol 
consumption are more prevalent and possibly 
more carcinogenic in males.11 
In 80 to 90% of cases, most (70-90%) HBV-
related HCC develops in cirrhotic livers.12 
Cirrhosis due to HBV or HCV is the leading 
risk factor for HCC: in 80 to 90% of cases, 
HCC occurs in the setting of cirrhosis.13 The 
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Abstract
Objective: Assess national and jurisdictional incidence and mortality trends for primary liver 
cancer in Australia.
Methods: Analysis of Australian Cancer Incidence and Mortality data published in 2017 by the 
AIHW. Age-standardised rates (ASR) for 1982 to 2014/2015. Piecewise linear regression was 
used to assess temporal trends. For the purposes of comparison, data were also extracted for all 
cancers with greater burdens of disease (lung, colorectal, breast, prostate, pancreatic, and brain 
cancers and melanoma of the skin). 
Results: Since 1982, the average annual percentage change (AAPC) for ASR incidence of liver 
cancer was 4.858% (95%CI 4.558-5.563). This marked a 306% increase from 1.822/100,000 
persons (95%CI 1.586-2.058) in 1982 to 7.396/100,000 persons (95%CI 7.069-7.723) in 
2014. AAPC for ASR mortality was 3.013% (95%CI 2.448-3.521): an increase of 184% from 
2.323/100,000 persons (95%CI 2.052-2.594) in 1982 to 6.593/100,000 (95%CI 6.290-6.896) 
in 2015. ASR incidence and mortality were highest in the NT (12.607/100,000 persons), VIC 
(8.229/100,000) and NSW (7.798/100,000). In comparison to the other selected cancers, higher 
AAPC for both incidence and mortality of liver cancer were observed.
Conclusion: Incidence and mortality associated with liver cancer have increased substantially 
in the past three decades, in contrast to the improved outcomes observed for many other 
cancers. Jurisdictional incidence rates reflect higher prevalence of hepatitis B and C.
Implications for public health: In the context of Australian cancer prevention and care 
programs, liver cancer is an outlier. Strategies to mitigate risk factors and improve surveillance 
of liver health for at-risk groups are urgently required.
Key words: primary liver cancer, hepatocellular carcinoma, incidence, mortality, surveillance
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five-year cumulative risk of developing HCC 
for patients with cirrhosis ranges between 
5% and 30%, depending on aetiology, region 
or ethnicity, and stage of cirrhosis.12,14 The 
highest risks are observed for individuals 
with HCV infection, of Asian ethnicity, and 
with decompensated disease.12,14 Further, 
non-alcoholic fatty liver disease (NAFLD) – 
associated with obesity, insulin resistance, 
and type 2 diabetes – is an increasingly 
recognised risk factor for HCC in developed 
countries.15,16 
The recently released Australian Cancer 
Incidence and Mortality books by the 
Australian Institute of Health and Welfare 
(AIHW) have, for the first time, provided 
incidence and mortality data for a broad 
range of cancers by states and territories. 
The current study will extract data for 
primary liver cancers (no breakdown by type 
available), with the aim to i) assess temporal 
trends for incidence and mortality of liver 
cancer; ii) assess jurisdictional differences for 
liver cancer incidence and mortality; and iii) 
compare national incidence and mortality 
data for other types of cancers. 
Methods 
The AIHW publishes the Australian Cancer 
Incidence and Mortality books based on data 
supplied by Australian cancer registries and 
the National Mortality Database.17 For the 
first time, in late 2017, the AIHW published 
a breakdown of this data by jurisdiction, i.e. 
for states and territories. Data for liver cancer 
was reported for all forms of liver cancer 
combined. Raw data and age-standardised 
rates (ASR) were extracted for liver cancer 
incidence (1982-2014) and mortality (1982-
2015) (incidence data were not available for 
2015) nationally and by jurisdictions. The 
AIHW did not report incidence data for: New 
South Wales for 2014, the Northern Territory 
for 1982-1994 and the Australian Capital 
Territory 1982-1985 due to “small numbers, 
confidentiality or concerns regarding data 
quality”.17 The ASRs were calculated by the 
AIHW using the Australian 2001 standard 
population.
For comparison, national incidence and 
mortality data were also extracted for the 
seven cancers that have greater burdens 
of disease than liver cancer. In this context, 
‘burden of disease’ refers to the combined 
impact of fatal and non-fatal disease, as 
measured by disability adjusted life years 
(DALYs).18 These cancers include: lung, 
colorectal, breast, prostate, pancreatic, brain 
and melanoma of the skin.17 The National 
Cancer Institute’s Joinpoint Regression 
software (version 4.6.0.0)19 was used to 
assess trends of ASR incidence and mortality 
over time. The software identifies whether 
increases (or decreases) in rates are linear or 
fluctuate. For fluctuating rates, the model 
identifies statistically significant changes in 
the slope of the line (i.e. joinpoints) using 
Monte Carlo permutations.19 Statistical 
significance was set at p<0.05. Average 
annual percentage change (AAPC) was 
calculated for the entire reporting period, and 
annual percentage change (APC) for each 
section between the joinpoints.
Results
Age-standardised incidence and 
mortality of liver cancer: 1982-
2014/2015
The ASR for incidence of liver cancer has 
steadily increased since 1982 (Table 1). For all 
persons, piecewise linear regression identified 
one joinpoint: between 1982 and 2006, the 
APC was 5.258% (95%CI 4.954-5.563) and 
between 2006 and 2014, the APC was lower 
at 3.668% (95%CI 2.816-4.526) (Figure 1a). 
AAPC over the entire time period was 4.858% 
(95%CI 4.558-5.159). Overall, ASR incidence 
increased by 306%, from 1.822/100,000 
(95%CI 1.586-2.058) persons in 1982 to 
7.396/100,000 persons (95%CI 7.069-7.723) in 
2014 (Table 2). 
For males, the AAPC observed was 4.597% 
(95%CI 4.387-4.808), with no joinpoints 
identified (Figure 1, supplementary file). 
For females, one joinpoint was observed: 
between 1982 and 2005 the APC was 5.907% 
(95%CI 5.322-6.495) and between 2005 and 
2014 the APC was 3.029% (95%CI 4.559-
5.623) (Figure 2, supplementary file). 
For ASR mortality (all persons), piecewise 
linear regression identified one joinpoint: 
between 1982 and 1986 APC was -0.474% 
(95%CI -4.967-4.232); subsequently, between 
1986 and 2015 APC was 3.504% (95%CI 3.356-
3.652) (Figure 1b). Across the entire reporting 
period, the AAPC was 3.013% (95%CI 2.448-
3.581) (Table 1), and ASR mortality increased 
by 184% from 2.323/100,000 persons (95%CI 
Table 1: Liver cancer ASR incidence and mortality: average annual percentage change (AAPC) and average 
percentage change (APC), 1982-2014/15.
AAPC 
(%)
95%CI P value Joinpoint 
section
APC (%) 95%CI P value
National Incidence 4.858 4.558-5.159 <0.001 1982-2006 
2006-2014
5.258
3.668
4.954-5.563
2.816-4.526
<0.001
<0.001
Mortality 3.013 2.448-3.581 <0.001 1982-1986
1986-2015
-0.474
3.504
-4.967-4.232
3.356-3.652
0.835
<0.001
NSW Incidencea 5.677 5.232-6.125 <0.001 n/a
Mortality 3.642 3.385-3.599 <0.001 n/a
VIC Incidence 4.593 4.226-4.961 <0.001 n/a
Mortality 2.845 2.563-3.128 <0.001 n/a
QLD Incidence 4.136 3.757-4.516 <0.001 n/a
Mortality 3.547 3.144-3.953 <0.001 n/a
WA Incidence 3.838 3.399-4.279 <0.001 n/a
Mortality 3.598 3.041-4.158 <0.001 n/a
SA Incidence 5.451 4.782-6.124 <0.001 n/a
Mortality 3.963 3.348-4.529 <0.001 n/a
 TAS Incidence 4.069 3.203-4.943 <0.001 n/a
Mortality 2.672 1.713-3.639 <0.001 n/a
ACT Incidenceb 3.538 2.079-5.017 <0.001 1986-1996
1996-2001
2001-2014
0.772
11.814
2.636
-1.515-3.112
4.479-19.663
1.852-3.426
0.494
0.003
<0.001
Mortality 2.269 0.980-3.574 0.001 n/a
NT Incidencec 1.526 -2.032-5.214 0.405 1994-2003
2003-2007
2007-2011
2011-2014
-2.985
-13.763
30.018
4.010
-5.570- -0.328
-25.236- -0.531
15.757-46.037
-3.941-12.620
0.032
0.043
0.001
0.296
Mortality 0.692 -0.787-2.193 0.349 n/a
Notes:
a: 2013 data as no incidence data was reported for 2014. 
b: First year reported: 1986.
c: First year reported 1994. 
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2.052-2.594) in 1982 to 6.593/100,000 (95%CI 
6.290-6.896) in 2015 (Table 2).
For males, no joinpoints were identified, 
with an AAPC of 3.150% (95%CI 2.972-3.327) 
observed (Figure 3, supplementary file). For 
females, the AAPC was 3.597 (95%CI 3.314-
3.880), with no joinpoints identified (Figure 4, 
supplementary file). 
Jurisdictional trends for ASR incidence 
and mortality of liver cancer
ASR incidence for all persons in 2014 was 
higher for the Northern Territory (NT) 
(12.607/100,000 persons; 95%CI 7.339-
17.867) than the national rate (7.396/100,000; 
95%CI 7.069-7.723), however, the wide 
95%CI for the NT indicates this difference 
was not statistically significant (Table 2). For 
other jurisdictions, ASR incidence ranged 
between 5.766/100,000 persons (Tasmania 
(TAS); 95%CI 4.022-7.509) and 8.229/100,000 
persons (Victoria (VIC); 95%CI 7.540-8.917). 
Piecewise linear regression was used to 
assess temporal trends in ASR incidence 
across jurisdictions (Table 1). In all states 
and territories, with the exception of the 
NT and the Australian Capital Territory 
(ACT), AAPC for ASR incidence increased 
steadily and significantly with no joinpoints 
identified. For the NT, three joinpoints were 
identified. Between 1994 and 2003, and 
2003 and 2007, negative APCs were reported 
(-2.985% (p=0.032) and -13.763% (p=0.043) 
respectively). Subsequently, between 2007 
and 2011, APC was 30.018% (p=0.001) and 
4.010% (p=0.296) between 2011 and 2014. 
The overall AAPC was 1.526% (95%CI -2.032-
5.214). For the ACT, two joinpoints were 
observed: between 1986 and 1996, the APC 
was 0.772% (p=0.494); between 1996 and 
2001 the APC increased to 11.814%, however 
this rate was characterised by a wide 95%CI of 
4.479-19.663. Subsequently, in 2001-2014 the 
APC was 2.636 (p<0.001). The overall AAPC 
was 3.538% (95%CI 2.079-5.017).
While ASR mortality was highest in the NT at 
11.252/100,000 persons, this estimate was 
characterised by a wide 95% confidence 
interval of 5.739-16.766 (Table 2). The ASR 
for mortality for the remaining jurisdictions 
ranged between 5.924/100,000 persons 
(95%CI 4.132-7.715) (TAS) and 7.329/100,000 
persons (95%CI 6.207-8.450) (South Australia 
(SA)). 
Across the reporting period, ASR mortality 
increased steadily and statistically 
significantly for most jurisdictions, with 
Figure 1a: ASR incidence liver cancer for all persons, Australia 1982-2014.
Notes:
^ Indicates that the Annual Per cent Change (APC) is significantly different from zero at the alpha=0.05 level. 
Final Selected Model: 1 Joinpoint.
Figure 1b: ASR mortality liver cancer for all persons, Australia 1982-2015.
Notes:
^ Indicates that the Annual Per cent Change (APC) is significantly different from zero at the alpha=0.05 level. 
Final Selected Model: 1 Joinpoint.
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AAPCs ranging between 2.269% for the ACT 
and 3.963% for SA. For the NT, the AAPC for 
mortality was 0.692% (p=0.349) (Table 1).
Changes in incidence and mortality 
of liver cancer compared with 
all cancers, cancers of the lung, 
colorectal, breast, prostate, pancreas, 
brain and melanomas of the skin: 
1982-2014/2015
Table 3 provides AAPC and APC for incidence 
and mortality for each of the selected cancers 
and for all cancers combined. For all cancers 
combined, the AAPC for ASR incidence 
between 1982 and 2014 was 0.759% (95%CI 
0.555-0.964). A decreased AAPC was observed 
for lung cancer (-0.376%, 95%CI -0.733- - 
0.017), and moderate increases for pancreatic 
cancer (0.496%, 95%CI 0.187-0.807), breast 
cancer (1.426%, 95%CI 1.085-1.769), 
melanomas of the skin (2.048%, 95%CI 1.540-
2.558) and prostate cancer (2.672%, 95%CI 
1.423-3.936). In comparison, a larger increase 
in incidence for liver cancer was observed, 
with an AAPC of 4.858% (95%CI 4.558-5.159).
For all cancers combined, the ASR mortality 
rate decreased between 1982 and 2015, with 
an AAPC of -0.780, 95%CI -0.843- -0.716). 
Negative AAPCs (indicating decreased 
mortality rates) were also observed for 
colorectal cancer (-2.302%, 95%CI -2.615- 
-1.987), lung cancer (-0.999, 95%CI -1.128- 
-0.869) and breast cancer (-1.425%, 95%CI 
-1.704- -1.145). Between 1982 and 2015, the 
ASR mortality for melanomas of the skin 
increased, with an AAPC of 0.514% (95%CI 
0.007-1.024). In contrast, the AAPC for liver 
cancer mortality was 3.013% (95%CI 2.448-
3.581).
Discussion
This paper provides an overview of the 
increasing burden of liver cancer experienced 
in Australia over the past three decades. 
Since 1982, ASR incidence for liver cancer 
increased by an average of 4.858% annually, 
and mortality by 3.013% annually. Over 
the entire reporting period, ASR incidence 
increased by 306% and mortality by 184%. 
These results are in keeping with a recently 
published study by Wallace and colleagues.3 
This study used data from the Australian 
Cancer Database to assess incidence and 
survival trends for HCC between 1982 and 
2014. The authors reported a slightly lower 
AAPC for ASR incidence of 4.46% (95%CI 
4.24-4.69 cf. 4.858% (95%CI 4.558-5.159)), 
however, this analysis was limited to HCC 
cases. For ASR incidence by sex, Wallace and 
colleagues reported an AAPC of 4.33% (95%CI 
4.09-4.57) for males and 4.21% (95%CI 3.81-
4.60) for females, similar to our estimates: 
4.597% (95%CI 4.387-4.808) for males, but 
slightly lower for females (5.089%, 95%CI 
4.559-5.623). Our inclusion of all primary 
liver cancers and Wallace’s focus on HCCs 
likely explains these differences, along with 
different approaches to coding of cases. 
The key drivers of both the observed and 
projected increases in incidence of liver 
cancer have been discussed by several 
authors.20-23 These include an ageing 
population, increasing prevalence of 
metabolic syndrome, NAFLDs and type 2 
diabetes, and increased migration from 
endemic HBV countries.14,24-27 HCV infections 
have also been a key risk factor for HCC, 
however, the uptake of direct-acting antiviral 
treatments in Australia is expected to result 
in HCV becoming a less commonly observed 
risk factor.3,28 
Universal vaccination for HBV, specifically 
for infants, is a cornerstone of the strategy 
to reduce prevalence, with 84% of infants 
globally having received a full schedule 
of vaccine doses as of 2015.29 However, 
estimates suggest that globally, only 9% of 
HBV infected people have been diagnosed, 
and of this group, 8% have received antiviral 
treatment.29 In the absence of treatment, the 
cumulative five-year incidence of cirrhosis 
for adults is 8-20%.30 In turn, the annual risk 
for developing HCC for cirrhotic HBV patients 
is 2-8%.31-33 The global burden of HBV and 
consequently HCC has been concentrated 
in developing countries, with >75% of HCC 
incidence occurring in Asian and sub-
Saharan African countries.34,35 With increasing 
migration occurring globally, it is essential 
that countries experiencing changing 
demographics, such as Australia, respond 
accordingly to these health issues. 
In concert with global increases in prevalence 
of obesity, are increased prevalence rates 
for NAFLD, largely driven by metabolic 
syndrome.16 NAFLDs include conditions of 
increasing severity of liver injury: simple 
steatosis, non-alcoholic steatohepatitis 
(NASH), cirrhosis and complications of 
cirrhosis in the absence of competing 
etiologies.16,36 These disorders are considered 
to represent hepatic manifestations of 
metabolic syndrome.36 A large review 
recently reported the annual incidence of 
HCC amongst NAFLD patients was 0.44 
per 1,000 person years (95%CI 0.29-0.66) 
and more specifically, for NASH the annual 
incidence rate was 5.29 per 1,000 person 
years (95%CI 0.75-37.56).16 Global prevalence 
Table 2: Changes in ASR incidence and mortality for liver cancer, 1982-2014/15
Incidence Mortality
1982 2014 Change over 
time
1982 2015 Change over 
time
ASR incidence 95%CI ASR incidence 95%CI ASR mortality 95% CI ASR mortality 95% CI
NSW 1.273 0.948-1.597 7.798a 7.209-8.388 513%a 2.389 1.934-2.843 7.010 6.470-7.551 193%
VIC 1.991 1.518-2.464 8.229 7.540-8.917 313% 2.214 1.706-2.721 6.267 5.677-6.856 183%
QLD 2.292 1.598-2.985 6.468 5.774-7.161 182% 2.338 1.631-3.045 6.034 5.372-6.697 158%
WA 1.744 0.938-2.550 6.755 5.763-7.747 287% 1.730 0.908-2.553 6.523 5.556-7.489 277%
SA 2.464 1.567-3.360 7.071 5.932-8.210 187% 2.451 1.543-3.358 7.329 6.207-8.450 199%
TAS 1.752 0.350-3.153 5.766 4.022-7.509 229% 2.982 1.134-4.830 5.924 4.132-7.715 99%
ACT 2.176b -0.047-4.822 6.190 3.603-8.777 184%b 2.923 0.385-6.231 5.990 3.593-8.386 105%
NT 9.375c 1.468-17.282 12.607 7.339-17.876 34%c 7.224 -0.951-15.399 11.252 5.739-16.766 56%
AUST 1.822 1.586-2.058 7.396 7.069-7.723 306% 2.323 2.052-2.594 6.593 6.290-6.896 184%
Notes:
a: 2013 data as no incidence data was reported for 2014. 
b: First year reported: 1986.
c: First year reported 1994.
Cocker et al.
2019 Online Australian and New Zealand Journal of Public Health 5
© 2019 The Authors
of NAFLD has been estimated to be 25.24% 
(95%CI 22.10-28.65),16 and prevalence often 
corresponds with rates of obesity.25 Highest 
rates of NAFLD were reported for the Middle 
East (32%), South America (31%), Asia (27%), 
the USA (24%) and Europe (14%) – no data 
have been reported for the general Australian 
community.16 With 63.4% of the adult 
Australian population overweight or obese,37 
studies are required to better understand the 
burden of NAFLD and NASH locally to inform 
responses.
Analysis of jurisdictional data showed 
that ASR incidence was highest in the NT 
(12.607/100,000 persons), VIC (8.229/100,000) 
and NSW (7.798/100,000). Accordingly, these 
states experience the highest burden of 
HBV and, with the exception of VIC, HCV. The 
National Notifiable Diseases Surveillance 
System provides estimates of unspecified 
(i.e. not incident) cases for HBV and HCV. In 
2017, the rate of unspecified HBV infections 
was highest in NT (38.0/100,000), NSW 
(29.2/100,000) and VIC (27.5/100,000).38 
For HCV unspecified cases, the rates were 
highest for the NT (59.0/100,000) and NSW 
(50.8/100,000). 
The national incidence and mortality data 
presented in this paper are in stark contrast 
to the trends observed for the seven cancers 
with a greater burden of disease in Australia 
than liver cancer (lung, colorectal, breast, 
prostate, pancreatic, brain, melanomas of the 
skin) and for all cancers combined. Similar 
findings have been reported in other recently 
published papers3,4 showing that in the 
context of Australian cancer prevention and 
care programs, liver cancer is an outlier.39 Two 
recommendations for surveillance for liver 
cancer have been published, both stating 
that people at high risk (albeit different 
definitions) of developing liver cancer should 
undergo six-monthly liver health checks, as 
prognosis is highly dependent on timing of 
diagnosis.40,41 However, the five-year survival 
rate of 18.5%42 suggests most liver cancers 
are diagnosed late in their development, in 
the absence of regular surveillance.43
National screening programs have 
contributed to improved outcomes for many 
patients. For example, BreastScreen Australia, 
which targets women aged 50-74 years, has 
contributed to a 32% decrease in mortality 
over the past two decades, and the National 
Cervical Screening Program has contributed 
to a 60% reduction in mortality since it 
commenced in 1991.44 However, screening 
programs for cancer can carry risks, such as 
Table 3: Average annual percentage change (AAPC) and average percentage change (APC) in ASR incidence and 
mortality for lung, colorectal, breast, prostate, pancreatic, brain, melanomas and all cancers combined, 1982-
2014/15
AAPC 
(%)
95%CI p value Joinpoint 
section
APC 
(%) 
95%CI p value
Lung cancers  Incidence -0.376 -0.733–-0.017 0.040 1982-2003
2003-2006
2006-2014
-0.472
1.372
-0.770
-0.582–-0.362
-2.423–5.315
-1.155–-0.384
<0.001
0.469
<0.001
Mortality -0.999 -1.128– -0.869 <0.001 1982-1994
1994-2015
-0.509
-1.278
-0.819–-0.198
-1.395–-1.160
0.002
<0.001
Colorectal 
cancers                
Incidence -0.120 -0.365–0.126 0.339 1982-1997
1997-2010
2010-2014
0.711
-0.277
-2.679
0.444–0.979
-0.581–0.029
-4.140–-1.196
<0.001
0.074
0.0014
Mortality -2.302 -2.615–-1.987 <0.001 1982-2000
2000-2006
2006-2015
-1.305
-5.648
-2.013
-1.519–-1.091
-7.024–-4.252
-2.616–-1.407
<0.001
<0.001
<0.001
Breast 
cancers                      
Incidence 1.426 1.085–1.769 <0.001 1982-1995
1995-2011
2011-2014
2.702
0.149
2.801
2.237–3.169
-0.131–0.429
-0.097–5.784
<0.001
0.285
0.058
Mortality -1.425 -1.704–-1.145 <0.001 1982-1994
1994-1999
1999-2014
-0.160
-3.523
-1.705
-0.490–0.174
-5.126–-1.893
-1.511–-17.899
0.333
<0.001
<0.001
Prostate 
cancers                  
Incidence 2.672 1.423–3.936 <0.001 1982-1990
1990-1994
1994-1998
1998-2008
2008-2014
3.118
20.105
-9.895
5.989
-4.869
0.990–5.290
12.251–28.509
-15.093–-4.379
4.975–7.014
-6.281–-3.436
0.006
<0.001
0.002
<0.001
<0.001
Mortality -0.375 -0.981–0.235 0.228 1982-1994
1994-1997
1997-2010
2010-2015
2.758
-4.411
-1.056
-3.480
2.299–3.220
-10.271–1.832
-1.412–-0.699
-4.701–-2.243
<0.001
0.154
<0.001
<0.001
Pancreatic 
cancers
Incidence 0.496 0.187–0.807 0.002 1982-2002
2002-2007
2007-2014
0.077
2.521
0.266
-0.104–0.258
0.772–4.301
-0.382–0.918
0.390
0.006
0.407
Mortality 0.047 -0.125–0.219 0.590 1982-1998
1998-2015
-0.218
0.298
-0.510–0.075
0.084–0.511
0.139
0.008
Brain cancers Incidence -0.002 -0.319–0.317 0.992 1982-2011
2011-2014
0.298
-2.852
0.174–0.423
-6.041–0.445
<0.001
0.087
Mortality -0.125 -1.104–0.863 0.803 1982-2002
2002-2005
2005-2015
0.276
-4.208
0.325
-0.057–0.609
-14.032–6.738
-0.470–1.127
0.100
0.421
0.409
Melanomas 
of the skin
Incidence 2.048 1.540–2.558 <0.001 1982-1987
1987-2002
2002-2014
7.205
1.865
0.196
4.181–10.317
1.404–2.329
-0.259–0.654
<0.001
<0.001
0.384
Mortality 0.514 0.007–1.024 0.047 1982-1987
1987-2000
2000-2011
2011-2015
3.304
-0.096
1.363
-3.188
0.872–5.795
-0.635–0.444
0.759–1.970
-5.278–-1.053
0.010
0.715
<0.001
0.005
Liver cancers Incidence 4.858 4.558–5.159 <0.001 1982-2006
2006-2014
5.258
3.668
4.954–5.563
2.816–4.526
<0.001
<0.001
Mortality 3.013 2.448–3.581 <0.001 1982-1986
1986-2015
-0.474
3.504
-4.967–4.232
3.356–3.652
0.835
<0.001
All cancers               Incidence 0.759 0.555–0.964 <0.001 1982-1990
1990-1994
1994-1998
1998-2008
2008-2014
1.154
3.536
-1.274
1.052
-0.699
0.873–1.436
2.390–4.695
-2.295–-2.584
0.877–1.227
-0.981–-0.416
<0.001
<0.001
0.018
<0.001
<0.001
Mortality -0.780 -0.843–-0.716 <0.001 1982-1994
1994-2015
-0.024
-1.209
-0.178–0.130
-1.265–-1.153
0.753
<0.001
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those observed for prostate cancer using 
prostate specific antigen testing.45 As such, 
new initiatives require careful consideration 
of the clinical, public health and health 
economics aspects. 
A strength of our study was use of national 
and jurisdictional data on cancer incidence 
and mortality. In Australia, notifications to 
cancer registries for most cancer diagnoses 
are legislated. The AIHW collates these data 
and has published more than three decades 
of incidence and mortality data for a range of 
cancers. An important limitation of this study 
is the potential for misclassification of cancer 
diagnoses. A study by Hong and colleagues46 
compared capture of HCC diagnoses by 
the Victorian Cancer Registry with data 
collected from several tertiary hospitals 
and other health service providers. They 
reported incidence from the hospitals/service 
providers was two-fold higher than reported 
from the Cancer Registry. This difference was 
largely due to the Registry’s use of histology 
as a basis for classification, whereas the 
researchers used diagnostic criteria from the 
American Association for the Study of Liver 
Diseases (AASLD) for this. In response the 
Victorian Cancer Registry reassessed all liver 
cancer diagnoses for the 1982-2014 period 
using clinical diagnostic guidelines, thereby 
reducing or eliminating under-reporting.4 
As such, the data reported in this study, 
particularly for other jurisdictions, may reflect 
an underestimate of the true number of liver 
cancer cases.
Liver cancer has been a low-prevalence 
cancer in developed countries including 
Australia. The demographic changes and 
increasing prevalence of overweight and 
obesity will likely contribute to increases 
in incidence in coming decades. The poor 
survival rates associated with liver cancer 
further contribute to the need for a greater 
focus on reducing this burden of disease. 
While substantial advances are being made 
regarding immunotherapy treatments for 
liver cancer, early diagnosis will likely remain 
a key factor in prognosis for several years to 
come. Current Australian recommendations 
for HCC surveillance differ and should be 
synthesised so health practitioners have a 
clear understanding of surveillance. Novel 
approaches are required to increase uptake 
and adherence to surveillance among at-risk 
groups, including people who have migrated 
from endemic HBV countries. 
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